Видео ютуба по тегу Medicines: Ipilimumab

CheckMate 8HW: expanded analysis of nivolumab & ipilimumab in MSI-H/dMMR mCRC
CheckMate 8HW: expanded analysis of nivolumab & ipilimumab in MSI-H/dMMR mCRC
Long term outcomes of CBM588 with nivolumab and ipilimumab in mRCC
Long term outcomes of CBM588 with nivolumab and ipilimumab in mRCC
🧬 When 1 + 1 = Cancer-Fighting Synergy
🧬 When 1 + 1 = Cancer-Fighting Synergy
Revolutionary Cancer Therapies: How Immunotherapy is Changing Everything |#shorts #reels
Revolutionary Cancer Therapies: How Immunotherapy is Changing Everything |#shorts #reels
FDA Approval: Opdivo + Yervoy for Hepatocellular Carcinoma Treatment
FDA Approval: Opdivo + Yervoy for Hepatocellular Carcinoma Treatment
Ipilimumab and Nivolumab Advancing Research on CTLA-4 in Cancer Therapy
Ipilimumab and Nivolumab Advancing Research on CTLA-4 in Cancer Therapy
Nuevos medicamentos de inmunoterapia contra el cáncer
Nuevos medicamentos de inmunoterapia contra el cáncer
A trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in R/R MDS
A trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in R/R MDS
A study of brentuximab vedotin, nivolumab, and ipilimumab in pediatric patients with R/R cHL
A study of brentuximab vedotin, nivolumab, and ipilimumab in pediatric patients with R/R cHL
A Phase II trial of azacitidine, ipilimumab, and nivolumab in previously untreated MDS
A Phase II trial of azacitidine, ipilimumab, and nivolumab in previously untreated MDS
Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of ...
Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of ...
Ipilimumab: Inmunoterapia Avanzada para el Cáncer | Descubre sus Beneficios
Ipilimumab: Inmunoterapia Avanzada para el Cáncer | Descubre sus Beneficios
O SUS deve fornecer o Ipilimumabe? Descubra como garantir seus direitos na Justiça!
O SUS deve fornecer o Ipilimumabe? Descubra como garantir seus direitos na Justiça!
Por que planos de saúde negam o Ipilimumabe, mesmo aprovado pela ANVISA para tratamento de câncer?
Por que planos de saúde negam o Ipilimumabe, mesmo aprovado pela ANVISA para tratamento de câncer?
Thomas Decaens - CO_02 Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) ou sorafénib...
Thomas Decaens - CO_02 Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) ou sorafénib...
NIBIT-ML1: ipilimumab and nivolumab with ASTX727 in PD-1 resistant melanoma
NIBIT-ML1: ipilimumab and nivolumab with ASTX727 in PD-1 resistant melanoma
Neoadjuvant ipilimumab plus nivolumab improves outcomes in resectable advanced melanoma
Neoadjuvant ipilimumab plus nivolumab improves outcomes in resectable advanced melanoma
Nivolumab plus ipilimumab improves efficacy versus standard of care in non-clear-cell renal cell...
Nivolumab plus ipilimumab improves efficacy versus standard of care in non-clear-cell renal cell...
NADINA trial: neoadjuvant ipilimumab + nivolumab shows superior EFS in resectable stage III melanoma
NADINA trial: neoadjuvant ipilimumab + nivolumab shows superior EFS in resectable stage III melanoma
NADINA trial: neoadjuvant ipilimumab + nivolumab vs. adjuvant nivolumab in stage III melanoma
NADINA trial: neoadjuvant ipilimumab + nivolumab vs. adjuvant nivolumab in stage III melanoma